Role of Angiotensin II in Insulin-induced Microvascular Activity

This study has been completed.
Information provided by:
Maastricht University Medical Center Identifier:
First received: November 30, 2009
Last updated: December 1, 2009
Last verified: December 2009
In this study we hypothesize infusion of Angiotensin II improves the insulin-induced microvascular dilatation and therefore insulin-mediated glucose uptake. Objectives: Does infusion of Angiotensin II increase insulin-mediated glucose uptake via enhanced insulin-mediated microvascular function in healthy subjects?

Condition Intervention
Insulin Sensitivity
Drug: Angiotensin II
Drug: Phenylephrine
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: Role of Angiotensin II in Insulin-induced Microvascular Activity

Resource links provided by NLM:

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • functional recruitment of capillaries in the skin [ Time Frame: January 2009 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • perfused capillary density in the nailfold [ Time Frame: January 2009 ] [ Designated as safety issue: No ]
  • Endothelium- (in)dependent vasodilatation of finger skin microcirculation [ Time Frame: January 2006 ] [ Designated as safety issue: No ]
  • Insulin sensitivity [ Time Frame: January 2009 ] [ Designated as safety issue: No ]

Enrollment: 18
Study Start Date: October 2006
Estimated Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Placebo
Drug: Placebo
Experimental: Angiotensin II
Angiotensin II
Drug: Angiotensin II
Angiotensin II
Active Comparator: Phenylephrine
Drug: Phenylephrine


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

1.18-60 years 2.Caucasian 3.Blood pressure <140/90 mmHg.

Exclusion Criteria:

  1. Obesity (BMI>27kg/m2)
  2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
  3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
  4. Smoking
  5. Alcohol use >4U/day
  6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
  7. Pregnancy
  8. Wearing contact lenses
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01024543

Maastricht University Medical Centre
Maastricht, P.o. Box 5800, Netherlands, Netherlands, 6202 AZ
Sponsors and Collaborators
Maastricht University Medical Center
Study Chair: CDA Stehouwer, Prof Maastricht University Medical Centre
  More Information

Responsible Party: Prof. CDA Stehouwer, Maastricht University Medical Centre Identifier: NCT01024543     History of Changes
Other Study ID Numbers: MEC 06-2-074 
Study First Received: November 30, 2009
Last Updated: December 1, 2009
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
Angiotensin II

Additional relevant MeSH terms:
Angiotensin II
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Autonomic Agents
Cardiotonic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nasal Decongestants
Neurotransmitter Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Protease Inhibitors
Protective Agents
Respiratory System Agents
Serine Proteinase Inhibitors
Vasoconstrictor Agents processed this record on May 22, 2016